Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Genome-wide Analysis of Single Nucleotide Polymorphisms of Brain Arteriovenous Malformations and Cerebral Aneurysm

This study has been terminated.
(Low enrollment)
Sponsor:
Information provided by (Responsible Party):
State University of New York - Upstate Medical University
ClinicalTrials.gov Identifier:
NCT01801488
First received: December 12, 2012
Last updated: November 19, 2014
Last verified: February 2013
  Purpose

Test single nucleotide polymorphisms (SNP's) in ruptured and unruptured aneurysm tissue to identify a genetic difference between the two types of aneurysms; and to test SNP's in arteriovenous malformation tissue to identify a genetic link.


Condition
Arteriovenous Malformations
Intracranial Aneurysm
Subarachnoid Hemorrhage

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Genome-wide Analysis of Single Nucleotide Polymorphisms of Brain Arteriovenous Malformations and Cerebral Aneurysm

Resource links provided by NLM:


Further study details as provided by State University of New York - Upstate Medical University:

Primary Outcome Measures:
  • Risk gene expression [ Time Frame: Within one week of sample collection. ] [ Designated as safety issue: No ]
    The samples will be frozen after collection and then analyzed.


Biospecimen Retention:   Samples With DNA

Tissue samples of intracranial arterial-venous malformations (AVM) or aneurysm and blood samples.


Enrollment: 5
Study Start Date: November 2011
Estimated Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts
AVM Patients
Patients receiving surgical intervention for an intracranial arterial-venous malformation.
Ruptured Aneurysm
Patients receiving surgical intervention for a ruptured intracranial aneurysm.
Unruptured Aneurysm
Patients receiving surgical intervention for an unruptured intracranial aneurysm.

  Eligibility

Ages Eligible for Study:   18 Years to 89 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients admitted to University Hospital.

Criteria

Inclusion Criteria:

  • All adult patients between the ages of 18 and 89 that are having open surgical resection of an AVM or clipping of an aneurysm will be included

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01801488

Locations
United States, New York
SUNY Upstate Medical University
Syracuse, New York, United States, 13210
Sponsors and Collaborators
State University of New York - Upstate Medical University
Investigators
Principal Investigator: Eric M Deshaies, MD SUNY Upstate Medical University Neurosurgery
  More Information

No publications provided

Responsible Party: State University of New York - Upstate Medical University
ClinicalTrials.gov Identifier: NCT01801488     History of Changes
Other Study ID Numbers: IRB#238810
Study First Received: December 12, 2012
Last Updated: November 19, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Aneurysm
Arteriovenous Malformations
Congenital Abnormalities
Hemangioma
Hemorrhage
Intracranial Aneurysm
Subarachnoid Hemorrhage
Brain Diseases
Cardiovascular Abnormalities
Cardiovascular Diseases
Central Nervous System Diseases
Cerebrovascular Disorders
Intracranial Arterial Diseases
Intracranial Hemorrhages
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Vascular Tissue
Nervous System Diseases
Pathologic Processes
Vascular Diseases
Vascular Malformations

ClinicalTrials.gov processed this record on November 25, 2014